Azeria Therapeutics, the world’s first pioneer factor drug discovery company, announces Series A investment from Sixth Element Capital

Azeria Therapeutics Limited, a newly formed drug discovery company, today announced that it has successfully raised £4 million in Series A fundraising from the £70 million CRT Pioneer Fund, managed by Sixth Element Capital LLP (6EC), a UK based fund manager.

Azeria, a spin out created by Sixth Element Capital and Cancer Research UK’s commercial partnerships team, is the world’s first pioneer factor drug discovery company developing breakthrough treatments for hormone resistant breast and prostate cancer patients, where there are significant areas of unmet clinical need.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...